Department of Radiation Physics, MD Anderson Cancer Center, Houston, TX, 77054, USA.
Department of Medical Physics, University of Wisconsin, Madison, WI, 53705, USA.
Med Phys. 2017 Oct;44(10):e391-e429. doi: 10.1002/mp.12462. Epub 2017 Aug 20.
The introduction of advanced techniques and technology in radiotherapy has greatly improved our ability to deliver highly conformal tumor doses while minimizing the dose to adjacent organs at risk. Despite these tremendous improvements, there remains a general concern about doses to normal tissues that are not the target of the radiation treatment; any "nontarget" radiation should be minimized as it offers no therapeutic benefit. As patients live longer after treatment, there is increased opportunity for late effects including second cancers and cardiac toxicity to manifest. Complicating the management of these issues, there are unique challenges with measuring, calculating, reducing, and reporting nontarget doses that many medical physicists may have limited experience with. Treatment planning systems become dramatically inaccurate outside the treatment field, necessitating a measurement or some other means of assessing the dose. However, measurements are challenging because outside the treatment field, the radiation energy spectrum, dose rate, and general shape of the dose distribution (particularly the percent depth dose) are very different and often require special consideration. Neutron dosimetry is also particularly challenging, and common errors in methodology can easily manifest as errors of several orders of magnitude. Task Group 158 was, therefore, formed to provide guidance for physicists in terms of assessing and managing nontarget doses. In particular, the report: (a) highlights major concerns with nontarget radiation; (b) provides a rough estimate of doses associated with different treatment approaches in clinical practice; (c) discusses the uses of dosimeters for measuring photon, electron, and neutron doses; (d) discusses the use of calculation techniques for dosimetric evaluations; (e) highlights techniques that may be considered for reducing nontarget doses; (f) discusses dose reporting; and (g) makes recommendations for both clinical and research practice.
放射治疗中先进技术和设备的引入极大地提高了我们为肿瘤提供高度适形剂量的能力,同时将相邻危及器官的剂量降至最低。尽管取得了这些巨大的进步,但人们仍然普遍关注非靶区正常组织的剂量;任何非靶区的辐射都应尽量减少,因为它没有治疗益处。随着患者在治疗后活得更长,出现迟发性效应(包括第二原发癌和心脏毒性)的机会增加。由于许多医学物理学家可能经验有限,这些问题的管理更加复杂,存在测量、计算、减少和报告非靶区剂量的独特挑战。在治疗野外,治疗计划系统的准确性显著降低,因此需要进行测量或其他一些方法来评估剂量。然而,由于在治疗野外,辐射能量谱、剂量率和剂量分布的一般形状(特别是百分深度剂量)都非常不同,通常需要特殊考虑,因此测量具有挑战性。中子剂量学也特别具有挑战性,方法上的常见错误很容易导致数量级的错误。因此,成立了 158 工作组,为物理学家在评估和管理非靶区剂量方面提供指导。特别是,该报告:(a)强调了非靶区辐射的主要关注点;(b)提供了临床实践中不同治疗方法相关剂量的大致估计;(c)讨论了用于测量光子、电子和中子剂量的剂量计的使用;(d)讨论了计算技术在剂量评估中的应用;(e)强调了可能考虑用于降低非靶区剂量的技术;(f)讨论了剂量报告;(g)为临床和研究实践提出了建议。